Impairment of the Schistosoma mansoni-specific immune responses elicited by treatment with praziquantel in Ugandans with HIV-1 coinfection.
Joseph, Sarah;
Jones, Frances M;
Laidlaw, Maureen E;
Mohamed, Gamal;
Mawa, Patrice A;
Namujju, Proscovia B;
Kizza, Moses;
Watera, Christine;
Whitworth, James AG;
Dunne, David W;
+1 more...Elliott, Alison M;
(2004)
Impairment of the Schistosoma mansoni-specific immune responses elicited by treatment with praziquantel in Ugandans with HIV-1 coinfection.
The Journal of infectious diseases, 190 (3).
pp. 613-618.
ISSN 0022-1899
DOI: https://doi.org/10.1086/422396
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
We show that Ugandan adults coinfected with Schistosoma mansoni and human immunodeficiency virus type 1 (HIV-1) are able to mount S. mansoni-specific immune responses but that few such responses increase after treatment with praziquantel (PZQ). Levels of soluble worm antigen (SWA)-specific immunoglobulin (Ig) G1, IgG2, IgG3, IgG4, interleukin (IL)-4, and IL-5 increased significantly in HIV-negative participants after treatment with PZQ, whereas most soluble egg antigen-specific antibody responses and levels of interferon- gamma were unaltered. Only levels of SWA-specific IL-5 increased in HIV-1-coinfected participants after treatment. These deficiencies in immune responses may account for the previously reported increased susceptibility to infection and reinfection with S. mansoni in individuals coinfected with HIV-1.
